Glaxo s Advair, AstraZeneca s Symbicort Pass FDA Panel Scrutiny (Bloomberg) Dec.
Glaxo s Advair, AstraZeneca s Symbicort Pass FDA Panel Scrutiny (Bloomberg)
Dec. 11 (Bloomberg) -- GlaxoSmithKline Plc s top-selling Advair and AstraZeneca Plc s Symbicort should remain available for asthma patients, a U.S. panel said, though studies suggest the drugs may increase the risk of death or hospitalizations.